An interventional study of insulin aspart in Type 2 Diabetes Mellitus, sponsored by Li Guangwei. Status unknown. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2012-05-01.
Sponsored by Li Guangwei · Not applicable, Interventional, and Treatment
It is well known that Long-term hyperglycemia (also known as glucose toxicity) contribute to impairment in islet β-cell function and development of insulin resistance. A growing body of evidence also indicates that this impairment inβ-cell function and insulin action could be restored after hyperglycemia is corrected by short-term intensive insulin therapy. In this study, we are determined to use the golden standard of insulin sensitivity evaluation in vivo-hyperinsulinemia euglycemic glucose clamp-to estimate insulin resistance improvement in patients before and after intensive insulin therapy, investigate first phase insulin secretion to evaluate β-cell function, examine the changes in insulin resistance and insulin secretion resulting from normalization of plasma glucose levels in both lean and obese patients by insulin pump therapy.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's planned enrollment of 130 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →This is the only study on the registry with Li Guangwei as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
AUC75-120 of Glucose Infusion Rate (GIR)
Time frame: after 2 weeks insulin pump intensive therapy, and one-year follow-up after termination of treatments
AUC0-10 of Acute Insulin Response (AIR) during IVGTT
Time frame: after 2 weeks insulin pump intensive therapy, and one-year follow-up after termination of treatments
No study locations are listed for this record.
This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.